The world's first dual-target SLE new drug, Taitasipu, comes out as a new weapon for experts to interpret and fight the "wolf"!

“，。”，，，。

，。

20213，()（：）：(SLE)“”——(：®)，2019，60，。

SLE“”，SLE。

，

?

？

，SLE？

SLE？？

SLE？

？

……

With these questions, Sina Medicine specially invited Professor Zhang Xuewu, the chief physician of the Department of Rheumatology and Immunology, Peking University People's Hospital, and Professor Zhao Dongbao, the chief physician of the Department of Rheumatology and Immunology, Changhai Hospital Affiliated to the Second Military Medical University, to give us professional answers.

What is systemic lupus erythematosus?

Professor Zhang Xuewu, Peking University People's Hospital

According to Professor Zhang Xuewu from Peking University People’s Hospital: “Lupus erythematosus is a typical autoimmune connective tissue disease.

In addition, regarding the hazards of lupus erythematosus, Professor Zhang Xuewu added: “Lupus erythematosus is the disease with the greatest impact and the highest mortality rate in rheumatism.

It is reported that the clinical manifestations of systemic lupus erythematosus are complex.

It is precisely because the cause of the disease is unknown that it is difficult to make breakthroughs in medical research in this field for many years.

Clinical needs urgently need to be met, "dual target" therapy new weapons came into being

According to the "Guidelines for Diagnosis and Treatment of Systemic Lupus Erythematosus in China 2020", there are currently about 5 million patients worldwide, of which the SLE patient population in mainland China exceeds 1 million, with a prevalence of about 70/100,000, ranking second in the world.

However, for a long time, the huge patient population has faced limited medical treatment.

Professor Zhao Dongbao, Changhai Hospital, Second Military Medical University

In this regard, Professor Zhao Dongbao from Changhai Hospital of the Second Military Medical University said: “Before the advent of biological agents, the clinically used drugs for the treatment of systemic lupus erythematosus mainly included glucocorticoids (prednisone, hydrocortisone, betamethasone).

"Almost when hormones and immunosuppressants are mentioned, patients frown, but we have no way.

Fortunately, the embarrassing situation of no new drugs in this field for many years has finally been gradually broken in recent years.

In 2011, belyumumab was approved for marketing by the FDA.

Then, after more than a year, Chinese SLE patients once again ushered in a great gospel.

In March 2021, my country's original blockbuster biologics-Rongchang Bio's Taltazep was officially listed in China conditionally.

According to Professor Zhao Dongbao, compared with traditional drugs, as a macromolecular drug, the biggest advantage of tytacept is through cell metabolism, not through liver and kidney metabolism, so it significantly reduces the most deadly disadvantage of traditional drugs-side effects .

In addition, in the view of Professor Zhao Dongbao, the biggest feature of Taitasipu is its "dual target" design.

"For a visual metaphor, the double target means that when you attack your opponent, you both punch him with your hand and kick him with your foot.

Undoubtedly, as a first-in-class drug with new mechanisms, new targets, and new structures in the world, it is much more difficult to develop dual targets of tytacept than single targets.

In addition, due to the good effect of tytacept on B lymphocytes, Professor Zhao Dongbao, who has participated in the clinical trials of tytazep for many years, also said: “In the future, tytazep has the potential to be used in other kinds of clinical trials with huge unsatisfactory Need autoimmune indications, such as the treatment of IgA nephritis, Sjogren’s syndrome, optic neuromyelitis, multiple sclerosis and myasthenia gravis.
At present, relevant trials in these areas have been launched, and many of these indications will also be launched globally Multi-center clinical research.
.
.
"

Improve patient accessibility, experts call for early access to medical insurance

The advent of new drugs has broken the awkward situation of "lack of doctors and drugs" in the medical field, but there is still a long way to go for each new drug to achieve "drug accessibility" for patients.

Since SLE requires long-term treatment, the price factor is extremely critical.

According to the latest news from Sina Pharmaceuticals, the current retail unit price of Tetazep is 2586 yuan per tube, and under the Early Benefit and Patient Assistance Program (PAP), the annual treatment cost is 78951 yuan, an average of 822 yuan per tube.
In other words, it is still not a small burden.

Regarding how to further improve the accessibility of patients’ medicines, Professors Zhang Xuewu and Zhao Dongbao both stated that innovative drugs came out after a long period of research, costing a large amount of research and development funds in the early stage, and biological drugs have the characteristics of high hard costs, so they were initially priced.
It's hard to get cheap.
We expect that in addition to improving patient accessibility through public welfare activities, such innovative drugs can also be included in medical insurance as soon as possible to benefit more patients.

In addition, it is worth noting that at present, Taltazep has shown certain curative advantages.
If the patient has a good recovery effect, the follow-up treatment costs will be correspondingly reduced, and the prognosis of the disease can also save a certain amount of expenditure.

"On the whole, whether it is efficacy or price, we still have a very large unfulfilled need for the treatment of patients with systemic lupus erythematosus, which requires the joint efforts of the government, enterprises, and institutions.
We look forward to the future Faster and better to benefit more patients in our country and even the world, and we also look forward to the advantages of tytazep being able to further achieve disease precision based on the advantages of targeted precision”, in the end, Professor Zhao Dongbao concluded.